Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
Pfizer has secured FDA approval for its Zirabev becacizumab biosimilar. But Genentech is citing 22 patents it says should bar the rival to its Avastin oncology brand.
You may also be interested in...
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
As Pfizer prepares for biosimilars launches in the US, its Biopharma unit has enjoyed 3% growth in the first half of 2019.
Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.